Tempus and Eric Lefkofsky Announce a Totaled $130 Million in Funding, Partnerships with Prestigious Medical Institutions

Tempus is a revolutionary startup in the healthcare industry. They specialize in using a technology called genomic sequencing in order to give doctors more options when creating customized cancer treatments and read full article.

The company was started in 2015 by Eric Lefkofsky and his long time business partner. The company recently announced that they had received $70 million in funding from the latest Series C funding round. The two corner stone investors in this funding round were Revolution Growth Investment Company and New Enterprise Associates (NEA). This round of funding brings the total investments to $130 million – a powerful funding number for a company that is just two years old and contact their.

Tempus is a healthcare technology startup that has an estimated $700 million evaluation, although this number has not been confirmed. The company is the brain child of tech innovator Eric Lefkofsky who has launched multiple successful companies in a variety of industries. This includes Groupon and Upstart Industries, two of his most well known successes and Eric’s lacrosse camp.

Lefkofsky is known as someone who consistently seeks out problems or potential problems and then uses his technology and business acumen to develop companies that solve those problems. He noticed that while there was a huge collection of information on specific cancer treatments, both from individual patients and in a clinical setting, that data was mostly found in the physician’s notes. While those notes were documented, they were not digitized for the most part and certainly not available in any type of easily accesible operations system.

Tempus seeks to change all that. By collecting data from physician’s notes and organizing them in a system that can be shared by physicians from Denver to Zurich and beyond, Tempus will become the world’s first operational system to give physician’s access to information that will allow them to provide data driven cancer care. In addition, Tempus utilizes genome sequencing and machine learning to revolutionize the way physicians can map out cancer care plans and their Facebook.

Tempus has already forged partnerships with Duke University’s Medical School, The Mayo Clinic and the Cleveland Clinic to bring the largest library of molecular and clinical data the world has ever seen and http://www.bizjournals.com/chicago/news/2016/10/20/groupon-founder-eric-lefkofsky-joins-steppenwolf.html.

Leave a Reply

Your email address will not be published. Required fields are marked *